This site is intended to use by healthcare professionals only

Bacteria friends
of your health

News

  • VSL#3 with Ferring at the 25th UEG Week

    VSL#3 with Ferring will partecipate to the 25th UEG Week (United European Gastroenerology) in Barcelona. UEG, or United European Gastroenterology, is a professional non-profit organisation combining all the leading European societies concerned with digestive health. For the 25th UEG

  • 9th PROBIOTICS, PREBIOTICS & NEW FOODS: VSL#3 Symoposium on Sept 11st

    From 10-12 September 2017 VLS#3 Pharma and Ferring will be in Rome to take part in 9th PROBIOTICS, PREBIOTICS & NEW FOODS NUTRACEUTICALS AND BOTANICALS Conference, that will be held at Università Urbaniana. 609

  • VSL#3 partecipates to LAB12, International Symposium on Lacid Bacteria

    From 27th to 31st August, VSL#3 will partecipate to The 12th Symposium on Lactic Acid Bacteria that will be held in the Congress Centre “Hotel Zuiderduin”, in Egmond aan Zee, Netherlands. 612

  • VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis

    Scientific article "The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis" published by Journal of Histochemistry & Cytochemistry reports the analitic results of VSL#3's effects on macrophages in acute trinitrobenzene sulfo

  • VSL#3 in ESPCG’s guideline

    "Probiotics in the management of lower GI symptoms in clinical practice" is the Practical reference guide developed by ESPCG (European Society for Primary Care Gastroenterology) the European Association of Academic General Practitioners with big interest in GI. The Guidelines has been written with t

  • VSL#3: efficacy in Pouchitis

    Pouchitis is a common complication in patients undergoing restorative proctocolectomy for ulcerative colitis. A systematic review made by The Rabin Medical Center, has supported the use of probiotics and prebiotics in pouchitis patients, aiming to clarify the place of these treatments in current the

  • Efficacy of probiotics in IBD

    VSL#3 appears to be effective in inducing remission in active UC, and probiotics may be as effective as 5-ASAs in preventing relapse of quiescent UC. However, the efficacy of probiotics in CD remains uncertain. That's the conclusion of a study conducted by a researchers team from the University

  • VSL#3 participates at the DDW 2017. Find us at AlfaSigma stand.

    VSL3 Pharmaceuticals participates at the DDW 2017 conference that takes place next May 6-9, 2017, at McCormick Place in Chicago, IL. A section of AlfaSigma stand (2227) is dedicated to VSL#3. Recognized as one of the top 50 medical meetings by HCEA, Digestive Disease Week® (DDW) is the world's l

  • Probiotics Are a Good Choice in Remission of Inflammatory Bowel Diseases

    Gut bacteria and bacterial metabolic pathways are important factors in initiation and progression of inflammatory bowel disease (IBD). A study conducted by Ganji-Arjenaki and Rafieian-Kopaei (Medical Plants Research Center, Shahrekord University of Medical Sciences, Iran) and performed on the studi

  • Cafeteria diet and probiotic therapy

    With a study on rats, researchers from University of New South Wales of Sydney, have investigated the impact of probiotics on gut health and cognitive function have examined if a probiotic could prevent diet-induced memory deficits. Rats were pre-exposed to vehicle, low or high doses of VSL#3 for